Correction to Earlier Release From Jewish Hospital and University of Louisville
Posted on: Friday, 24 July 2009, 16:05 CDT
LOUISVILLE, Ky., July 24 /PRNewswire-USNewswire/ -- In today's announcement regarding the use of stem cells in the treatment of heart failure, we failed to make a critical distinction. Louisville researchers and physicians have performed the world's first phase-one FDA-approved clinical trial using "c-kit-positive" adult cardiac stem cells to treat heart disease. The clinical trial is being conducted by a team of University of Louisville physicians at Jewish Hospital, in collaboration with Dr. Piero Anversa and his team at the Brigham and Women's Hospital in Boston.
Following the press conference Roberto Bolli, Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and Director of UofL's Institute for Molecular Cardiology, stated, "Another clinical trial is being conducted at another facility. The difference between what we have done and what another institute nationally has done is that we have injected a pure population of stem cells, the c-kit-positive cells. The other institution injected cardiosphere-derived cells, which are a mixture of primitive and partially differentiated cells, complicating the recognition of the actual therapeutic cell. Our study involves a specific, well-characterized population of undifferentiated cells: the c-kit-positive cardiac stem cells are self-renewing, clonogenic and multipotent, which are the fundamental properties of stem cells."
This is a small, but distinct difference than the procedure performed last month in California.
We regret any misunderstanding or confusion.
SOURCE Jewish Hospital
Source: PR Newswire
Related Articles
- Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes
- Florida Hospital and Burnham Institute Announce New Executive Director and Facility for Clinical Research Institute
- University of Ottawa Heart Institute Trial Finds Popular Blood Clotting Drug Does Not Improve Patient Outcomes and Increases Risk of Bleeding
- Omeros and The Parkinson's Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
- Roskamp Institute's Associate Clinic Director Named Chairperson of the Alzheimer's Disease Initiative Advisory Committee
- For the 14th Year in a Row, Cleveland Clinic Heart Center Is Ranked No. 1 in U.S. News & World Report 'America's Best Hospitals' Survey
- ViaCord and Children's Hospital Oakland Research Institute Announce 100th Cord Blood Transplant
- The Cleveland Clinic Heart Surgery Program at LakeWest Hospital Achieves Zero Percent Mortality in 2006
- Shriners Hospitals Opens Brittle Bone Disease Clinic
- UK National Institute for Clinical Excellence Backs the Use of HIFU for the Treatment of Localized Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds